Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.34 |
| ▸ | TCF7L2 | Q9NQB0 | 5/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 2/20 | 0.33 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676561 | 1.00 | CNR1 (0.36) | CNR1CNR2CTNNB1TCF7L2MDM2 | |
| SCHEMBL1676651 | 0.89 | GCGR (0.37) | CNR1CNR2MDM2GCGREGFR | |
| SCHEMBL1676655 | 0.89 | GCGR (0.37) | CNR1CNR2MDM2GCGREGFR | |
| SCHEMBL1676529 | 0.87 | CNR1 (0.38) | CNR1CNR2MDM2GCGREGFR | |
| SCHEMBL1676533 | 0.87 | CNR1 (0.38) | CNR1CNR2MDM2GCGREGFR | |
| SCHEMBL1676645 | 0.86 | CNR1 (0.37) | CNR1CNR2MDM2EGFR | |
| SCHEMBL1676644 | 0.86 | CNR1 (0.37) | CNR1CNR2MDM2EGFR | |
| SCHEMBL1676779 | 0.84 | GCGR (0.38) | GCGRNPSR1 | |
| SCHEMBL1676777 | 0.84 | GCGR (0.38) | GCGRNPSR1 | |
| SCHEMBL1676900 | 0.83 | LMNA (0.36) | CNR1CNR2SMN1; SMN2P2RX7EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | CNR1 3344/4885CNR2 3387/4885CTNNB1 3642/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | CNR1 3344/4885CNR2 3387/4885CTNNB1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.